- Profile Image
- Name
- Gail Hecht
- Degree
- M.D.
- Rank
- Professor
- Primary Department
- Medicine
- Education
- Medical School
- Loyola University Chicago Stritch School of Medicine
- Residencies
- University of Minnesota Hospital and Clinics Internal Medicine
- Fellowships
- Brigham and Women's Hospital/Harvard Medical School Gastroenterology
- Hobbies
- Exercise
- Summaries
- The focus of Dr. Hecht’s research is host-pathogen interactions with specific emphasis on enteropathogenic Escherichia coli and enterohemorrhagic E. coli. Her goal is to determine how the bacterial effector proteins that are translocated into intestinal epithelial cells by these pathogens alter host cell physiology including tight junction barrier function, active ion transport processes, and the innate immune response. Her research is funded by both the NIH and the VA. She also has an interest in the gut microbiome and its impact on intestinal function and health.
- Publications
- McFarland, LV; Hecht, G; Sanders, ME; Goff, DA; Goldstein, EJC; Hill, C; Johnson, S; Kashi, MR; Kullar, R; Marco, ML; Merenstein, DJ; Millette, M; Preidis, GA; Quigley, EMM; Reid, G; Salminen, S; Sniffen, JC; Sokol, H; Szajewska, H; Tancredi, DJ; Woolard, K Recommendations to Improve Quality of Probiotic Systematic Reviews With Meta-Analyses. JAMA network open ; 6 12
- Orenstein, R; Hecht, G; Harvey, A; Tillotson, G; Khanna, S Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent infections. Open forum infectious diseases ; 10 9
- Mills, JC; Casanova, JE; Hecht, G Presentation of the AGA Distinguished Achievement Award in Basic Science to James R. Goldenring, MD, PhD, AGAF. Gastroenterology ;
- Chopra, T; Hecht, G; Tillotson, G Gut microbiota and microbiota-based therapies for infection. Frontiers in medicine ; 9
- Kralicek, SE; Jenkins, C; Allegretti, JR; Lewis, JD; Osman, M; Hecht, GA Transmission of the potential pathogen atypical enteropathogenic E. coli by fecal microbiota transplant. Gastroenterology ;
- Laine, L; Hecht, G Presentation of the Julius M. Friedenwald Medal to Sheila E. Crowe, MD. Gastroenterology ;
- Tapia, R; Hecht, GA Spef1/CLAMP binds microtubules and actin-based structures and regulates cell migration and epithelia cell polarity. Annals of the New York Academy of Sciences ;
- Kralicek, SE; Sitaraman, LM; Kuprys, PV; Harrington, AT; Ramakrishna, B; Osman, M; Hecht, GA Clinical manifestations and stool load of atypical enteropathogenic E. coli infections in U.S. children and adults. Gastroenterology ;
- Orenstein, R; Dubberke, ER; Khanna, S; Lee, CH; Yoho, D; Johnson, S; Hecht, G; DuPont, HL; Gerding, DN; Blount, KF; Mische, S; Harvey, A Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infectious Diseases ; 22 1
- Tapia, R; Kralicek, SE; Hecht, GA Enteropathogenic (EPEC) Recruitment of PAR Polarity Protein Atypical PKC? to Pedestals and Cell-Cell Contacts Precedes Disruption of Tight Junctions in Intestinal Epithelial Cells. International journal of molecular sciences ; 21 2
- Wilcox, MH; McGovern, BH; Hecht, GA The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Infection: Current Understanding and Gap Analysis. Open forum infectious diseases ; 7 5
- Carlino, MJ; Kralicek, SE; Santiago, SA; Sitaraman, LM; Harrington, AT; Hecht, GA Quantitative analysis and virulence phenotypes of atypical enteropathogenic (EPEC) acquired from diarrheal stool samples from a Midwest US hospital. Gut microbes ; 12 1
- Tapia, R; Perez-Yepez, EA; Carlino, MJ; Karandikar, UC; Kralicek, SE; Estes, MK; Hecht, GA Sperm Flagellar 1 Binds Actin in Intestinal Epithelial Cells and Contributes to Formation of Filopodia and Lamellipodia. Gastroenterology ; 157 6
- Fuhler, GM; Hecht, GA 2019 Gut Microbiota for Health World Summit. Gastroenterology ; 158 1
- Dubberke, Erik R; Lee, Christine H; Orenstein, Robert; Khanna, Sahil; Hecht, Gail; Gerding, Dale N Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases ; 67 8
- Dubberke, ER; Lee, CH; Orenstein, R; Khanna, S; Hecht, G; Gerding, DN Results from a Randomized Placebo-Controlled Clinical Trial of a RBX2660-a Microbiota-based Drug for the Prevention of Recurrent Clostridium difficile Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America ;